CSL is undervalued in High Tax Scenario

Ramsee

Not Invested

Community Contributor

Published

10 Apr 25

Updated

11 Apr 25

n/a

Ramsee's Fair Value

n/a

-34.4%

-1.2%

-34.4%

-1.2%

You can edit this narrative until May 14 2:40 AM. Then, changes will post as Updates.

Author's Valuation

AU$263.3330.1% undervalued

Ramsee's Fair Value

Narrative

Updates1

Shared on 11 Apr 25

Fair value Increased 9.97%

Ramsee has decreased discount rate from 6.6% to 4.0%.

Ramsee'sFair Value

AU$263.33

30.1% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

4.37%

Biotech revenue growth rate

9.24%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.00%

Calculation

US$3.68b

Earnings '30

26.33x

PE Ratio '30

US$96.82b

Market Cap '30

US$96.82b

Market Cap '30

489.00m

No. shares '30

US$198.00

Share Price '30

US$198.00 Share Price '30

Discounted to 2025 @ 4.00% p.a.

US$162.74

Fair Value '25

US$162.74 Fair Value '25

Converted to AUD @ 1.6181 USD/AUD Exchange Rate

AU$263.33

Fair Value '25